Drug Profile
Research programme: vaccine therapeutics - Liquidia Technologies
Alternative Names: Multivalent PRINT nanoparticle pneumococcal vaccine - Liquidia TechnologiesLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Liquidia Technologies
- Developer Liquidia Technologies; Malaria Vaccine Initiative; PATH
- Class Bacterial vaccines; Cancer vaccines; Influenza virus vaccines; Pneumococcal vaccines; Synthetic vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Infections; Influenza virus infections; Malaria; Pneumococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral, Injection)